LC
ELVN icon

Lindbrook Capital’s Enliven Therapeutics ELVN Stock Holding History

Lindbrook Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$276 Sell
14
-7
-33% -$151 ﹤0.01% 2689
2024
Q4 		$473 Buy
+21
New +$544 ﹤0.01% 2634

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Lindbrook Capital's ELVN Position: Q1 2025 in Review

Lindbrook Capital reduced its Enliven Therapeutics (ELVN) stake by 33% in Q1 2025, selling an estimated $151 and leaving 14 shares worth $276. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

Lindbrook Capital first reported a position in ELVN in Q4 2024 and has held it in 2 quarters since. The position peaked at $473 in Q4 2024. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

  • Lindbrook Capital held 14 shares of Enliven Therapeutics worth $276 as of Q1 2025.
  • Lindbrook Capital sold 7 Enliven Therapeutics shares in Q1 2025, an estimated $151.
  • Enliven Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2689 holding.
  • Lindbrook Capital first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Lindbrook Capital's Enliven Therapeutics position peaked at $473 in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.